Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, Nystrom HF, Jansson S, Jörneskog G, Karlsson FA et al. Incidence of hyperthyroidism in Sweden. European Journal of Endocrinology 2011 165 899-905. (doi:10.1530/EJE-11-0548).
Kaguelidou F, Carel JC & Leger J. Graves' disease in childhood: Advances in management with antithyroid drug therapy. Hormone Research 2009 71 310-317. (doi:10.1159/000223414).
Zimmerman D & Gan-Gaisano M. Hyperthyroidism in children and adolescents. Pediatric Clinics of North America 1990 37 1273-1295.
Hamburger JI. Management of hyperthyroidism in children and adolescents. Journal of Clinical Endocrinology and Metabolism 1985 60 1019-1024. (doi:10.1210/jcem-60-5-1019).
Glaser NS & Styne DM. Predictors of early remission of hyperthyroidism in children. Journal of Clinical Endocrinology and Metabolism 1997 82 1719-1726.
Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefberg Z & Philip M. Thyrotoxicosis in prepubertal children compared with pubertal and post pubertal patients. Journal of Clinical Endocrinology and Metabolism 2000 85 3678-3682. (doi:10.1210/jcem.85.10.6922).
Barrio R, Lopez Capapé M, Martinez-Badas I, Moreno JC, Carrillo A & Alonso M. Graves' disease in children and adolescents: response to long-term treatment. Acta Paediatrica 2005 94 1583-1589. (doi:10.1080/08035250500252872).
laser NS, Styne DM & Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: A prospective, multicenter study. Pediatrics 2008 121 e481-e488. (doi:10.1542/peds.2007-1535).
Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P & Léger J. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. Journal of Clinical Endocrinology and Metabolism 2008 93 3817-3826. (doi:10.1210/jc. 2008-0842).
Franklyn JA & Boelaert K. Thyrotoxicosis. Lancet 2012 379 1155-1166. (doi:10.1016/S0140-6736(11)60782-4).
Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, Delvecchio M, Peroni E, Pistorio A & Corrias A. Graves' disease in children: Thyroid-stimulating hormone receptor antibodies as remission markers. Journal of Pediatrics 2014 164 1189-1194. (doi:10.1016/j. jpeds.2013.12.047).
Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C & French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. Journal of Clinical Endocrinology and Metabolism 2012 97 110-119. (doi:10.1210/jc. 2011-1944).
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocrine Practice 2011 17 456-520. (doi:10.4158/EP.17.3.456).
Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3, 5, 30-triiodothyronine in thyroid secretion. Metabolism 1984 33 379-392. (doi:10.1016/0026-0495(84)90203-8).
Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, Mozai T & Hershman JM. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease. Annals of Internal Medicine 1984 100 372-375. (doi:10.7326/0003- 4819-100-3-372).
Hegedus L, Hansen J, Bech K, Kampmann J, Jensen K, Andersen E, Hansen P, Karstrup S & Bliddal H. Thyroid stimulating immunoglobulins in Grave's disease with goitre growth, low thyroxine and increasing triiodothyronine during PTU treatment. Acta Endocrinologica 1984 107 482-488.
Sempé M, Pedron G & Roy-Pernot MP. Auxologie, méthodes et séquences. Paris: Théraplix, 1979. 205 p. 18.
Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C & Charraud A. Body mass index variations: centiles from birth to 87 years. European Journal of Clinical Nutrition 1991 45 13-21.
Royston P & Wright E. A method for estimating age-specific reference intervals based on fractional polynomials and exponential transformation. Journal of the Royal Statistical Society 1998 161 79-101. (doi:10.1111/1467-985X.00091).
Chen J & Ladenson P. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Grave's disease. Journal of Clinical Endocrinology and Metabolism 1986 63 102-106. (doi:10.1210/jcem-63-1-102).
Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A & Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. Journal of Clinical Endocrinology and Metabolism 2007 92 2157-2162. (doi:10.1210/jc.2006-2135).
Williams K, Nayak S, Beker D, Reyes J & Burmeister L. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have you learned? Journal of Clinical Endocrinology and Metabolism 1996 82 1727-1733.
Bianco A, Salvatore D, Gereben B, Berry M & Larsen P. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine Reviews 2002 23 38-89. (doi:10.1210/edrv.23.1.0455).
Ito M, Toyoda N, Nomura E, Takamura Y, Amino N, Iwasaka T, Takamatsu J, Miyauchi A & Nishikawa M. Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3-5-30-triiodothyronine-predominant Graves' disease. European Journal of Endocrinology 2011 164 95-100. (doi:10.1530/EJE-10-0736).
Laurberg P, Vestergaard H, Nielsen S, Christensen S, Seefeldt T, Hellebreg K & Pedersen KM. Sources of circulating 3, 5, 30-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. Journal of Clinical Endocrinology and Metabolism 2007 92 2149-2156. (doi:10.1210/jc.2007-0178).
Matsumoto C, Ito M, Yamakawa N, Yoshida H, Date A, Watanabe M, Hidaka Y, Iwatani Y, Miyauchi A & Takano T. Genes that characterize T3-predominant Graves' thyroid tissues. European Journal of Endocrinology 2013 168 137-144. (doi:10.1530/EJE-12-0507).
Hollander CS, Mitsuma T, Shenkman L, Stevenson C, Pineda G & Silva E. T3-toxicosis in an iodine-deficient area. Lancet 1972 16 1276-1278. (doi:10.1016/S0140-6736(72)92650-5).
Reinwein D, Benker G, Konig MP, Pinchera A, Schatz H & Schleusener A. The different types of hyperthyroidism in Europe. Results of a prospective survey of 924 patients. Journal of Endocrinological Investigation 1988 11 193-200. (doi:10.1007/BF03350134).
Carle A, Knudsen N, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB & Laurberg P. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: A population-based study. European Journal of Endocrinology 2013 169 537-545. (doi:10.1530/EJE-13-0533).
Pedersen IB, Knudsent N, Carlé A, Schomburg L, Kohrle J, Jorgensen T, Rasmussen LB, Ovesen L & Laurberg P. Serum selenium is low in newly diagnosed Graves' disease: A population based-study. Clinical Endocrinology 2013 79 584-590. (doi:10.1111/cen.12185).
